Gilead beats estimates, raises 2025 guidance, driven by strong HIV and liver drug sales and multiple launches planned for ...
For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...
People living with HIV who smoke are currently more likely to die from lung cancer than from HIV-related causes. Two cancer ...
Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...
Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for ...
Two owners of Cambridge-based Safe Chain Solutions have been found guilty of multiple charges including introducing black ...
More than 230 people became infected with HIV in Indiana, worsened by delayed action from former Gov. Mike Pence. Experts and ...
Investor's Business Daily on MSN
Gilead Sciences Dives As HIV Drug Misses Bullish Buy-Side Expectations
Big-name biotech Gilead Sciences issued a mixed third-quarter report late Thursday, with product sales coming in below ...
Patrick and Charles Boyd bought more than $90 million of the illicit drugs and sold them to unwitting customers in South ...
More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...
Researchers used cryo-EM to study how the HIV enzyme integrase arranges in 3D to slip its DNA into the host genome and pack ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback